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Abstract
Background: We investigated efficacy of inhaled nitric oxide (NO) in modulation of metabolism
of phosphatidylcholine (PC) of pulmonary surfactant and in anti-inflammatory mechanism of mature
lungs with inflammatory injury.
Methods: Healthy adult rats were divided into a group of lung inflammation induced by i.v.
lipopolysaccharides (LPS) or a normal control (C) for 24 h, and then exposed to: room air (Air),
95% oxygen (O), NO (20 parts per million, NO), both O and NO (ONO) as subgroups, whereas
[3H]-choline was injected i.v. for incorporation into PC of the lungs which were processed
subsequently at 10 min, 4, 8, 12 and 24 h, respectively, for measurement of PC synthesis and
proinflammatory cytokine production.
Results:  LPS-NO subgroup had the lowest level of labeled PC in total phospholipids and
disaturated PC in bronchoalveolar lavage fluid and lung tissue (decreased by 46–59%), along with
the lowest activity of cytidine triphosphate: phosphocholine cytidylyltransferase (-14–18%) in the
lungs, compared to all other subgroups at 4 h (p < 0.01), but not at 8 and 12 h. After 24-h, all LPS-
subgroups had lower labeled PC than the corresponding C-subgroups (p < 0.05). LPS-ONO had
higher labeled PC in total phospholipids and disaturated PC, activity of cytidylyltransferase, and
lower activity of nuclear transcription factor-κB and expression of proinflammatory cytokine
mRNA, than that in the LPS-O subgroup (p < 0.05).
Conclusion:  In LPS-induced lung inflammation in association with hyperoxia, depressed PC
synthesis and enhanced proinflammatory cytokine production may be alleviated by iNO. NO alone
only transiently suppressed the PC synthesis as a result of lower activity of cytidylyltransferase.
Background
Surfactant dysfunction and deficiency is one of the most
important mechanisms in acute lung injury (ALI) and
acute respiratory distress syndrome (ARDS) in adults and
children [1,2]. ARDS is often encountered as a complica-
tion of various diseases or critical conditions, such as
pneumonia, sepsis, pancreatitis, trauma, burn injury, car-
diovascular and gastrointestinal operations, or as a part of
multiple organ system failure. Pathogenesis of ALI and
ARDS involves intrapulmonary neutrophil accumulation
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and inflammatory damage of alveolar structure, leading to
impairment of lung mechanics and gas exchange, pulmo-
nary hypertension secondary to hypoxic intrapulmonary
vasoconstriction, and increased vascular-to-alveolar per-
meability. To prevent the development of ARDS from pul-
monary infection and septic lung injury, inhaled nitric
oxide (iNO) was introduced primarily as a selective pul-
monary vasodilator to alter hypoxemic vasoconstriction.
However, no long term efficacy was found in overall sur-
vival and ventilation time shortening despite the fact that
iNO significantly reduces pulmonary hypertension and
intrapulmonary shunt, thereby improving systemic oxy-
genation [3-7]. Attempts are made in recent years to verify
therapeutic efficacy of iNO in ALI/ARDS, and it is pro-
posed as a bridging therapy for severe hypoxemia to obvi-
ate more invasive and expensive strategies [5,8]. In
contrast, iNO may be considered as a free radical and exert
cytotoxicity, as it combines with superoxide at near diffu-
sion-limited rates to produce highly reactive oxidant per-
oxynitrite (ONOO-) which may cause secondary
surfactant damage. Peroxynitrite is a potent oxidizing and
nitrating agent that damages a wide spectrum of biologi-
cal molecules such as DNA, lipids, and proteins [9]. NO is
implicated as both prooxidant and antioxidant. It can be
harmful or protective, depending on the concentration
and duration of exposure and on the presence of other
molecules as well as homeostasis of NO metabolism and
catabolism. iNO is usually used in combination with high
oxygen supply in critical conditions. Its excess of oxidative
radical products in hyperoxia mediate adverse effects of
oxygen. Lamb et al (10) found that iNO increases 3-nitro-
tyrosine, a marker for ONOO- formation, in bronchoalve-
olar lavage fluid (BALF) of ARDS patients, however, they
did not find correlation between BALF nitrotyrosine levels
and clinical outcome. In contrast, Honda et al [11] dem-
onstrated that tyrosine nitration was stopped in a direct
lipopolysaccharides (LPS) insult in the lungs of adult rats
treated with iNO at 20 ppm.
Pulmonary surfactant consists of phospholipids,
hydrophilic and hydrophobic proteins that line up in the
inner alveolar surface and prevent alveolar collapse. Disat-
urated phosphatidylcholine (DSPC) is a major surface-
active lipid component of surfactant that is produced,
together with other saturated and unsaturated phospholi-
pids, by alveolar type II epithelial cells (AEC II). Pulmo-
nary surfactant protein A is the most abundant surfactant
protein, and its nitrated form may be detected in edema
fluid of patients with ALI. Whether iNO in hyperoxia
would have any adverse effects in surfactant phospholipid
synthesis in inflammatory injury of the mature lung
remains an unanswered question. Therefore, we hypothe-
sized that impaired PC synthesis in LPS-induced lung
inflammatory injury may further be aggravated in hyper-
oxia, and that therapeutic dosage of iNO may not exert
adverse effects in PC synthesis but anti-inflammation and
anti-oxidant effects in the mature lungs. We investigated
de novo synthesis and secretion of PC by incorporation of
isotope labeled precursor, [Methyl-3H]-choline chloride,
in adult rat lungs with inflammatory injury and subjected
to a long term inhalation of NO with or without high level
of oxygen, in relation to activity of cytidine triphosphor-
ylate: phosphocholine cytidylyltransferase (CCT), a key
rate-limiting enzyme in synthesis of PC, as well as activity
of nuclear transcription factor-κB (NF-κB) and mRNA lev-
els of proinflammation cytokines in the lung tissue.
Materials and methods
Materials
LPS (E. coli 055:B5, Catal. No. L2880), cytidine 5'-diphos-
phocholine (CDP-choline), cytidine 5'-triphosphate
(CTP), oleic acid, phosphatidylcholine (PC), phospho-
choline chloride, trichloroacetic acid were purchased
from Sigma Chemical (St. Louis, MO). Activated charcoal
was obtained from Fisher Chemical (Fair Lawn, NJ). The
[methyl-3H] choline chloride (84.0 Ci/mmol), phospho-
ryl [methyl-14C] choline (55.0 mCi/mmol), cytidine 5'-
diphospho [methyl-14C] choline (55.0 mCi/mmol) were
purchased from Amersham Pharmacia Biotech (Bucking-
hamshire, UK). A rabbit polyclonal antibody to a syn-
thetic peptide (DFVAHDDIPYSSA) corresponding to
residues 164–176 of rat liver CCT [12] was purchased
from Boster Biotech (Wuhan, China).
Experimental animals
The Children's Hospital Scientific Committee, Fudan Uni-
versity, approved the experimental protocol and animal
care. We followed the principles of laboratory animal care
(NIH publication No. 86–23, revised 1985) and Chinese
national regulation for experimental animal care. Healthy
Sprague-Dawley male rats (180 to 200 g) were purchased
from Bikai Ltd. (Shanghai, China). Lung inflammatory
injury was induced by bolus LPS (2 mg/kg, i.v.) 24 hours
prior to experiment, and these rats were referred as LPS
group. A normal control group (C) received sterile NaCl
injection in an identical manner. Both LPS and C groups
were then randomly allocated to subgroups exposed to:
room air (Air), 95% oxygen (O), room air and 20 ppm
NO (NO), 95% oxygen and 20 ppm NO (ONO). NO gas
was prepared in 1,000 ppm, and provided with a mass
flow controller. Concentration of NO was measured with
an NO/NO2  electrochemical analyzer (NOxBOX Plus,
Bedfont Scientific Inc, Rochester, UK). The device was cal-
ibrated with 25 ppm NO and 1 ppm NO2 as a standard
calibration gas prepared from this laboratory. No differ-
ences in body weight were found between the two groups
and their sub-groups (n = 8 at 4 and 24 h, n = 6 at 8 and
12 h each), and all the animals survived the designated
experimantal period.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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[3H]-Choline incorporation into PC
To measure surfactant PC synthesis in vivo, [Methyl-3H]
choline chloride at 15 µCi in 15 µl diluted in 0.2 ml saline
was injected intravenously for each of the animals fol-
lowed by exposure of specific gas for 10 minute, 4, 8, 12
and 24 hours, respectively, and then the animals were sac-
rificed by overdose of intraperitoneal pentobarbital (70
mg/kg), followed by exsanguinations via abdominal
aorta. The lungs were perfused with 20 ml of cooled nor-
mal saline via right ventricle to remove the residual blood.
BALF was collected and pooled through 2 volumes of 6 ml
(approximately 30 ml/kg body weight) of cooled saline
washed in and out of the lungs, each for 4 times (totally 8
times). Its supernatant collected after removal of cell
debris by centrifugation was stored at -20°C until analysis
for surfactant phospholipids, proteins and the special
radioactivity of phospholipid. The BAL cells were counted
with a cytometer. Another 2 lavages were performed and
collected fluid was deserted. The lungs were removed and
the tissue was immediately homogenized in 6 ml NaCl,
10 ml methanol and 20 ml chloroform at -20°C to stop
further isotope incorporation according to the method
described by Jacobs et al [13].
Total phospholipids (TPL) and DSPC in BALF and lung
tissue after BAL were recovered following chloroform-
methanol (2:1) extraction and treatment of lipid extracts
with OsO4 in carbon tetrachloride by aluminum phos-
phate column chromatography according to the methods
described by Mason et al [14] and Bartlett [15]. Aliquots
of TPL and DSPC in chloroform were dried under pure N2,
then subjected to routine treatment for scintillation
counting measured with a Beckman multifunctional liq-
uid scintillation counter (LS 6500, Beckman Coulter,
Toronto, ON, Canada). Special radioactivity of 3H was
expressed as count per minute (cpm). Total proteins (TP)
in BALF was measured by Lowry's method [16].
In a separate cohort, five animals of each subgroup were
used for histological examination of the lungs (see
below). Eight rats of each subgroup were used for CCT
activity and immunoblot analysis, RT-PCR for CCT mRNA
expression, and an assay for NF-κB and mRNA levels of
pro-inflammatory cytokines in lung tissue according to
the methods described elsewhere (see below). All these
animals were not subjected to the isotope injection but
identical exposure to specific gases.
Histological and morphometric examination of lungs
The lungs from each subgroups not subjected to isotope
were perfused for 30 min via the pulmonary arteries with
4% formaldehyde at a pressure of 65 cm H2O while both
lungs were first inflated to an airway pressureof 30 cm
H2O for 1 min, and then deflated to 10 cm H2O for the
rest of time. Representative lung tissue blocks from all
lung lobes were embedded in paraffin. Sections stained
with hematoxylin-eosin were examined by light micros-
copy for evidence of lung injury, which was scored for
edema, and neutrophil infiltration. A score scaled at 0 to
4 represents the severity: 0 for no or very minor, 1 for
modest and limited, 2 for intermediate, 3 for widespread
or prominent, and 4 for widespread and most prominent
[17]. These works were performed in a blinded manner so
that investigators were not able to identify the treatment
and outcome of the animals until completion of the
measurement.
Wet-to-dry lung weight ratio (W/D)
A piece of lung tissue from right lung was cut and its wet
weight was determined in an automatic electronic balance
AP250D (Ohaus, Florham, NJ). The lung tissue was then
put in an oven at 80°C for 48 h and weighed again to
obtain its dry weight for calculation of wet-to-dry lung
weight ratio [17].
Cell fractionation
Left lung tissue was homogenated in a buffer of 145 mM
NaCl, 50 mM tris (hydroxymethyl) aminomethane (Tris)-
HCl (pH 7.4), 50 mM NaF, and 2.5 mM EDTA (hereafter
referred to as Tris-saline). The homogenate was centri-
fuged at 3000 g for 10 min. The resulting supernatant was
centrifuged at 20,000 g for 10 min to obtain a post mito-
chondrial supernatant. After an aliquot of this superna-
tant was stored, microsomal and cytosolic fractions were
obtained by centrifugation at 100,000 g  for 60 min.
Microsomes were resuspended in a volume of Tris-saline
equal to that of the cytosol. All steps were carried out at
4°C. Protein content of samples was determined [16].
Homogenates and cell fractions were stored at -70°C until
cytidylyltransferase activity and protein levels were meas-
ured.
Cytidylyltransferase activity assay
CCT activity was assayed in the forward direction by meas-
uring the rate of incorporation of [methyl-14C] phospho-
choline into CDP-choline. The incubation medium (0.1
ml) contained 20 mM Tris-HCl (pH 7.8), 6 mM MgCl2, 4
mM CTP, 1.6 mM [methyl-14C] phosphocholine (specific
activity: 0.625 µCi/µmol), and 30 µg protein. The CCT
activity of homogenate was assayed in the presence of 0.5
mM phosphatidylcholine: oleic acid (1:1 molar ratio) ves-
icles. These vesicles were prepared by sonication as
described previously. The assays for microsomal and
cytosolic were performed in the absence of 0.5 mM phos-
phatidylcholine: oleic acid (1:1 molar ratio) vesicles. After
30 min of incubation at 37°C, the reaction was stopped
by addition of 0.1 ml of 25% (w/v) trichloracetic acid and
0.5 ml of charcoal suspension (6% charcoal in 50 mM
phosphocholine). The samples were placed on ice and
[methyl-14C] CDP-choline was isolated as described previ-Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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ously. The recovery (67–72%) of CDP-choline was deter-
mined in each set of assays by adding a known amount of
[methyl-14C] CDP-choline to a complete assay mixture.
All assays were corrected for background and recovery
[18].
RT-PCR for CCT mRNA
Total RNA was isolated by a single-step isolation proce-
dure using an RNA-STAT® isolation solution. A sample (2
µg) of total RNA was treated with DNase 1 to remove
DNA contaminants, followed by incubation with 25 mM
EDTA in a total volume of 50 µl. Samples were incubated
at 37°C for 60 min, followed by 3 min at 94°C. Aliquots
(2 µl) of the resulting RT-PCR products were incorporated
into PCR reactions. Initially, we used these methods to
detect the housekeeping gene, glyceraldehyde phosphate
dehydrogenase (GAPDH), as an internal standard to
assess the quality of the RNA, to correct for loading artifact
of the RNA gels, and to ensure that there was no DNA con-
tamination of the RNA preparations. The PCR was com-
posed of 30 cycles: 94°C for 45 s, 60°C for 45 s, 72°C for
2 min, followed by 72°C for 7 min. The primer sequences
for CCT-PCR were as follows:
RM CT 1 5'-AGTGCAGCGCTGTGCAGTC-3' and
RM CT 2 5'-ACAGGTCACAGCCTTGCAC-3',
These sequences correspond to +199 to +218 and +1160
to +1179, respectively, of rat CCT cDNA sequence produc-
ing a 980 bp fragment [18]. The rat-specific primers used
for GAPDH resulted in a 452 bp fragment. The primer
sequences for GAPDH-PCR were as follows:
RM GAPDH 1 5'-ACCACAGTCCATGCCATCAC-3' and
RM GAPDH 2 5'-TCCACCACCCTGTTGCTGTA-3'.
Immunoblot detection of CCT
Cytosol or particulate fraction proteins (30 µg) were sep-
arated electrophoretically on 12% (wt/vol) sodium
dodecyl sulfate-polyacrylamide gels and transferred to
polyvinylidene difluoride membranes (Millipore, Bed-
ford, MA). After incubation with 5% blotting grade
blocker (Bio-Rad, Hercules, CA) in buffer A (24 mM Tris
and 0.5 mM NaCl, pH 7.4) for 2 h at 24°C, the membrane
was then incubated in buffer B (buffer A plus 3% blocker,
0.1% Tween-20, and 0.1% bovine serum albumin) with
anti-rat CT serum (1:500) for 18 h at 24°C. After washing
three times with 0.1% Tween-20, the membrane was incu-
bated with sheep anti-rabbit immunoglobulin G-horse-
radish peroxidase (1:2000) in buffer B for 90 min, then
washed twice with 0.3% Tween-20 in buffer A and twice
with 0.1% Tween-20 in buffer A. The membrane was
soaked in ECL reagent (Amersham, ArlingtonHeights, IL)
for 2 min and exposed to X-ray film for up to 5 min [19].
Determination of Nuclear Transcription Factor-κB (NF-
κB), mRNA of proinflammatory cytokines in lung tissue
Details of preparation of nuclear protein fractions and
electrophoretic mobility shift assay (EMSA) to detect DNA
binding activity of NF-κB were described by Cao et al [20],
and results were expressed arbitrarily as densitometric
unit. Expression of mRNA of tumor necrosis factor-α
(TNF-α), cytokine-induced neutrophil chemoattractant-1
(CINC-1), and interleukin-10 (IL-10) in lung tissue. The
methods of RNA extraction and reverse transcription were
described above in the RT-PCR for CCT mRNA. PCR was
performed on 2 µl of reverse transcriptase product, con-
taining Taq DNA polymerase, dNTP, buffer, and 0.5 µM
concentrations of each gene-specific forward and reverse
primers (obtained from Shenggong Biotech, Shanghai,
China) in a total volume of 50 µl. Gene-specific oligonu-
cleotide primers are listed in Table I. The methods of PCR
were described by Haddad et al [21]. The level of gene
Table 1: Biochemical analysis of bronchoalveolar lavage fluid at 24 h of different gas exposure.
Subgroup TPL (mg/kg) DSPC (mg/kg) TP (mg/kg) DSPC/TP (µg/mg)
C-Air 7.8 ± 1.6 3.4 ± 0.4 19.2 ± 04.9 186 ± 38.9
LPS-Air 6.3 ± 1.6 * 2.7 ± 0.7 ** 29.9 ± 6.0 # 89 ± 12.4 ##**
C-ONO 7.4 ± 2.0 3.3 ± 0.5 18.0 ± 3.8 188 ± 22.9
LPS-ONO 5.4 ± 1.2 2.2 ± 0.7 38.3 ± 12.0 ## 63 ± 20.3 ##*
C-O 8.1 ± 1.2 3.3 ± 0.6 19.8 ± 6.3 176 ± 33.4
LPS-O 4.1 ± 0.8 ## 1.6 ± 0.4 ## 46.2 ± 8.8 ## 35.0 ± 3.8 ##
C-NO 7.8 ± 1.8 3.5 ± 0.7 20.2 ± 6.6 179 ± 31.0
LPS-NO 5.9 ± 1.6 2.5 ± 0.8 33.2 ± 6.8 ## 75 ± 14.7 ##**
Definition of subgroups and parameter abbreviations: C, normal control group; LPS, lipopolysaccharides-treated group; Air, room air; NO, 20 ppm 
nitric oxide; ONO, 95% O2 and 20 ppm NO; O, 95% O2. TPL, total phospholipids; DSPC/TPL, disaturated phosphatidylcholine to TPL ratio; TP, 
total proteins; DSPC/TP, DSPC to TP ratio. Values represent means ± SD (n = 8). Statistical analysis: # P < 0.05, ## P < 0.01 versus the 
corresponding C subgroup; * p < 0.05, ** p < 0.01 versus LPS-O.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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expression of each transcript was normalized to that of the
housekeeping gene GAPDH.
Malondialdehyde (MDA) was measured for lipid peroxi-
dation with thiobarbituric acid assay [22]. Lung tissue
approximately 0.2 g was homogenized with 9-fold 0.5%
HTAB (0.01 mol/L sucrose, 0.01 mol/L Tris-HCL, 0.1
mmol/L EDTA-Na2). The mixture was then centrifuged at
4000 g for 15 min, 0.2 ml supernatant or standards, 0.2
ml 8.1% sodium dodecyl sulfate, 1 ml of 50% acetic acid,
3 ml of 0.8% aqueous thiobarbituric acid, and 1 ml of
deionized water were added to cuvettes. After heating to
95°C for 40 minutes, the mixture was centrifuged at 3,000
g for 15 min, and the absorbance of the upper liquid layer
was determined at 532 nm. A standard curve using tetrae-
thyoxypropane was used to express the data in terms of
MDA equivalents.
Myeloperoxidase (MPO) was determined for the relative
number of PMN sequestered in the lungs. Lung tissue
samples (200 mg) were homogenized in 1.8 ml of 0.5%
of hexadecyltrimethylammonium bromide in 50 mM
potassium phosphate buffer (pH 6.0) with detergent in an
ice bath. Samples were sonicated to disrupt the granules
and solubilize the MPO in the hexadecyltrimethylammo-
nium bromide. Samples were then centrifuged at 8,000 g
for 10 min at 4°C. Assay buffer comprised 750 µl of 1.7
mM H2O2 and 650 µl of 2.5 mM 4-aminoantipyrine with
2% phenol. An aliquot of 100 µl of supernatant of each
sample was mixed into 1.4 ml of assay buffer at room tem-
perature. Results are expressed as relative change in
absorbance per minute at 460 nm. One unit of MPO was
defined as causing a change of 1.0 absorbance and the
data were expressed as U/g lung tissue [23].
Statistics
Data are presented as means and standard deviation (SD).
Continuous parametric data were subjected to analysis of
variance(ANOVA) followed by Student-Newman-Keuls
post-hoc test for between-group differences. For categori-
cal data, a Kruskal-Wallis ANOVA was used to detect dif-
ferences across the groups, followed by the Wilcoxon-
Mann-Whitney test for differences between the two
groups. A p value < 0.05 was regarded as statistically sig-
nificant.
Results
[3H] Choline incorporation into PC
In the C-Air subgroup synthesis of PC was peaked at 4 h
as reflected by specific radioactivity in [3H] TPL and [3H]
DSPC, and decreased by approximately 40–50% at 24 h
exposure. At 4 h, the incorporation of [3H] TPL in LPS-NO
was significantly lower than that in all other subgroups,
either in BALF or in the total lungs (BALF plus lung tissue,
Fig. 1), respectively (decreased by 46~59%, p < 0.01).
Synthesis of total phospholipids (TPL) in the mature rat lungs Figure 1
Synthesis of total phospholipids (TPL) in the mature rat lungs. 
The amounts of radiolabeled TPL (cpm/g body weight) 
recovered from bronchoalveolar lavage fluid (BALF), and in 
the total lungs [i.e. in both lung tissue after lavage and BALF], 
were determined in lipopolysaccharides (LPS)-treated (black 
diagrams) and non-treated control (C, white) rats. Definition 
of subgroups (n = 8 each): Air, room air; ONO, 95% oxygen 
and nitric oxide in 20 parts per million; O, 95% oxygen; and 
NO, nitric oxide 20 parts per million. Definition of each sub-
set figures: A-B, 4 h; C-D, 24 h; A and C, [3H] TPL in BALF; B 
and D, [3H] TPL in the total lungs. Values are means ± SD. §§ 
p < 0.01 versus all other subgroups; # p < 0.05, ## p < 0.01 
versus the corresponding C subgroup.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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These differences were not significant at 8 and 12 h in
which incorporation of TPL was lower by 10–20% in all
the LPS-subgroups than in the corresponding C-sub-
groups. At 24 h, the incorporation of PC in all the LPS sub-
groups was significantly lower than that in the
corresponding C-subgroups. A similar trend over time was
seen in [3H] DSPC of each subgroups, which was about
20–25% in amount compared to that of the TPL (data not
shown). The incorporation of [3H] TPL and [3H] DSPC in
LPS-O was significantly lower than in the other LPS-sub-
groups (decreased by 24–47%). The secretion of PC was a
ratio of [3H] TPL in BALF versus that in the total lungs
(BALF+lung tissue). The secretion of TPL and DSPC
between C- and LPS-subgroups was not significantly dif-
ferent at the five time points. Initial secretion rate was 10–
15% at 10 min and 4 h, peaked at 12 h for [3H] TPL (20%)
and [3H] DSPC (23%). At 24 h, the secretion of TPL and
DSPC was decreased by 33~39% and 18~21%, respec-
tively, compared with the peak value, respectively (data
not shown).
PC content
In general, TPL, DSPC and DSPC/TP were lower, and TP
higher, in LPS-subgroups than in the corresponding C-
subgroups at 4, 8, 12 and 24 h exposure. The levels of
DSPC/TP, as a major marker of surfactant deficiency and/
or vascular-to-alveolar permeability, in all the LPS-sub-
groups were consistently lower than those in the corre-
sponding C-subgroup at different time points, and
reaching statistical significance at 8, 12 (data no shown)
and 24 h (p < 0.05) (Table 1). At 4 h, levels of TPL (7.6 ±
1.2 mg/kg) and DSPC (3.2 ± 0.7 mg/kg) in BALF of the
LPS-NO have no significant difference with those in LPS-
Air. Compared to the data at 4 h, both TPL and DSPC in
BALF of the LPS-O at 24 h were significantly lower than
those in LPS-Air subgroup (decreased by 35% and 41%,
respectively) (Table 1). Results of biochemical analysis of
TPL and DSPC in the lung tissue are shown in Table 2.
Cytidylyltransferase activity assay
The CCT activity in the lung tissue homogenate was meas-
ured in the presence of lipid activator, and it represented
the total amount of CCT. We found that at 4 h, there were
no significant difference of CCT activity in homogenates
and cytosol among all the subgroups, however, CCT activ-
ity in microsome subfraction (0.75 +0.05 nmol/min/mg
protein) in LPS-NO was lower than all other subgroups (p
< 0.01). At 24 h, in all the LPS-subgroups, CCT activities
Table 2: Biochemical analysis of lung tissue at 24 h of different gas exposure.
Subgroup TPL (mg/kg) DSPC (mg/kg) DSPC/TPL (%)
C-Air 102 ± 20.2 23.7 ± 3.9 24.1 ± 6.7
LPS-Air 96.2 ± 15.7 21.3 ± 4.2 * 22.6 ± 5.1
C-ONO 106 ± 24.3 23.7 ± 3.6 23.5 ± 6.3
LPS-ONO 101 ± 24.6 20.7 ± 4.1 * 20.8 ± 3.2
C-O 107 ± 19.9 26.6 ± 3.7 25.4 ± 5.3
LPS-O 83.2 ± 17.2 16.0 ± 2.7 ## 19.7 ± 3.6
C-NO 110 ± 21.4 27.4 ± 4.1 25.4 ± 4.3
LPS-NO 105 ± 17.1 24.1 ± 3.6 ** 23.4 ± 4.6
For definition of subgroups and parameter abbreviations, see figure 1 legends. Values represent means ± SD (n = 8). Statistical analysis: ## P < 0.01 
versus the corresponding C subgroup; * p < 0.05, ** p < 0.01 versus LPS-O.
Table 3: Lung injury score
4 h 24 h
Subgroup Edema Infiltration Edema Infiltration
C-Air 0 ± 0 0.1 ± 0.2 0 ± 0 0.1 ± 0.2
LPS-Air 0.5 ± 0.4# 0.8 ± 0.3# 0.6 ± 0.2## 1.2 ± 0.3##
C-ONO 0.2 ± 0.3 0.1 ± 0.2 0.2 ± 0.3 0.2 ± 0.4
LPS-ONO 0.7 ± 0.4# 0.9 ± 0.4# 0.8 ± 0.4# 1.4 ± 0.2##*
C-O 0.1 ± 0.2 0.3 ± 0.5 0.3 ± 0.3 0.3 ± 0.4
LPS-O 0.7 ± 0.3# 1.0 ± 0.4# 1.1 ± 0.2## 1.9 ± 0.4##+
C-NO 0.1 ± 0.2 0 ± 0 0.2 ± 0.3 0.2 ± 0.3
LPS-NO 0.6 ± 0.2# 1.1 ± 0.4# 0.7 ± 0.4# 0.7 ± 0.3#+
(K-W) p = 0.001 p < 0.001 p < 0.001 p < 0.001
Definition of abbreviations: (K-W), Kruskal-Wallis test of analysis of variance. Values are means ± SD (n = 5). For group definitions, see Table 1 
legends. Statistical analysis: # p < 0.05, ## p < 0.01 vs the corresponding control subgroup; + p < 0.05 vs LPS-Air; * p < 0.05 vs LPS-O.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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in homogenate, microsomal and cytosolic preparation
were consistently lower than those of the corresponding
C-subgroups (-20–30%, p < 0.01, Fig. 2A). CCT activity in
microsome subfraction of LPS-O was significantly lower
than that of the other LPS-subgroups (p < 0.05, Fig. 2B),
suggesting a mechanism by which hyperoxia or iNO
decreases activity of CCT is different from that by LPS.
Measurement of CCT mRNA and protein
Average values of CCT mRNA/GAPDH mRNA were about
0.5–0.6 between LPS- and C-subgroups at both 4 and 24
h, with no significant significance. CCT protein/α-actin in
Cytidine triphosphate: phosphocholine cytidylyltransferase  (CCT) activity in lung homogenates, microsomes, and  cytosol at 24 h of different gas exposure in control (white  diagram) and lipopolysaccharides-treated (black) rats Figure 2
Cytidine triphosphate: phosphocholine cytidylyltransferase 
(CCT) activity in lung homogenates, microsomes, and 
cytosol at 24 h of different gas exposure in control (white 
diagram) and lipopolysaccharides-treated (black) rats. Defini-
tion of the subgroups see Fig. 1 legends. Definition of the 
subset figures: A in the presence of lipid activator; B and C, in 
the absence of the lipid activator. Values are means ± SD in 
each subgroup (n = 8) and expressed as nmol/min/mg pro-
tein. * p < 0.05, ** p < 0.01 versus LPS-O subgroup; ## p < 
0.01, versus the corresponding C subgroups.
Protein contents of cytidine triphosphate: phosphocholine  cytidylyltransferase (CCT) in lung homogenates (A) and  microsomes (B) at 24 h of different gas exposure in control  (white diagram) and lipopolysaccharides-treated (black) rats Figure 3
Protein contents of cytidine triphosphate: phosphocholine 
cytidylyltransferase (CCT) in lung homogenates (A) and 
microsomes (B) at 24 h of different gas exposure in control 
(white diagram) and lipopolysaccharides-treated (black) rats. 
Definition of the subgroups see Fig. 1 legends. Western blot-
ting for CCT protein quantitated with densitometric analysis 
of the autoradiograms. Values are means ± SD in each sub-
group (n = 6) and expressed as arbitrary units. * p < 0.05, ** 
p < 0.01 versus LPS-O subgroup; ## p < 0.01, versus the 
corresponding C-subgroups.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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Photomicrographs of histological findings in the animal lungs at 48 h of endotoxin exposure corresponding to 24 h of different  gas exposure in control (C) and lipopolysaccharides (LPS)-treated rats Figure 4
Photomicrographs of histological findings in the animal lungs at 48 h of endotoxin exposure corresponding to 24 h of different 
gas exposure in control (C) and lipopolysaccharides (LPS)-treated rats. Definition of the subgroups see Fig. 1 legends. All the 
lungs were fixed by pulmonary arterial perfusion at deflation pressure of 10 cm H2O for 30 min. Definition and characteristics 
of subset figures: A, C-Air, well aerated alveoli; B C-ONO, nearly normal alveolar structure alternative with over expanded 
alveoli; C, C-O, mild atelectatic alveoli; D, C-NO, nearly normal alveolar structure alternative with over expanded alveoli; E, 
LPS-Air, severe inflammation and edema; F LPS-ONO, severe inflammation and collapsed alternative with over expanded alve-
oli; G, LPS-O, very severe inflammation and collapse of alveoli; H, LPS-NO, mild collapse of alveoli. Hematoxylin and eosin 
staining; original magnification ×100.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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lung homogenates and microsomes were 0.8–1.0 in C-
subgroups at 4 and 24 h, with no significant differences.
At 4 h, the level of this parameter for microsomal subfrac-
tion of LPS-NO was lower than all other subgroups (p <
0.05). In contrast, all LPS subgroups had significantly
lower levels in the lung homogenates (0.5) than the cor-
responding C-subgroups (-50%, p < 0.01, Fig. 3A), how-
ever, at 24 h, in the microsomes this value was
significantly lower (0.3) in LPS-O than in the LPS-NO
(Fig. 3B, p < 0.01).
Histologic and morphometric examination of the lungs
As shown by lung injury score in Table 3, there were
prominent edema, infiltration of neutrophils in the lungs
of animals in the LPS-subgroups. At 24 h, in the LPS-O,
there was deteriorated infiltration of neutrophils, but sig-
nificantly alleviated infiltration of neutrophils was found
in the LPS-NO (Fig. 4).
Measurement of W/D and WCC
At 24 h, average values of W/D were higher in all the LPS
subgroups (5.3–5.9) than that in the C subgroups (4.5–
4.7, p < 0.01), and that for WCC were also higher in the
former (10.6–26.5 × 106/rat) than in the latter (2.0–2.6 ×
106/rat, p < 0.01), with the highest values for the LPS-O
(26.5 ± 3.5 × 106/rat, p < 0.05 vs. LPS-ONO).
Measurement of NF-κB by EMSA
The DNA-binding activity of NF-κB in lung tissue assayed
with EMSA at 4 h and 24 h revealed that the binding activ-
ity from LPS-treated rats was enhanced compared with the
corresponding C-subgroups. At 24 h, the binding activity
in LPS-O was higher than that of LPS-Air. On the contrary,
the values in LPS-NO were lower than that of LPS-Air (Fig.
5A and 5B).
Measurement of proinflammatory cytokine mRNA, MPO 
and MDA
At 4 h, there was no significant difference of mRNA
expression of TNF-α, CINC-1 and IL-10, and MPO and
MDA levels in lung tissue among all the LPS-subgroups
(Fig. 6A, C, E, and Fig 7A and 7C). After 24 h exposure,
LPS-O had higher levels of TNF-α and CINC-1 mRNA,
MPO and MDA than LPS-Air subgroup. LPS-NO subgroup
had lower levels of TNF-α, CINC-1 and IL-10 mRNA,
MPO and MDA than LPS-Air subgroup. LPS-ONO sub-
group had lower levels of TNF-α mRNA and MPO than
LPS-O subgroup (Fig. 6B, and Fig 7B). At all the time
points, the LPS subgroups had higher levels of all the
parameters than the corresponding C-subgroups.
Discussion
In the present study, we found that inhaled NO caused a
transient depression of PC synthesis in association with
suppression of activity and production of CCT for PC syn-
thesis in endotoxin-induced lung injury, however, this
effect did not persist. It suggests that the therapeutic dose
of iNO should not cause adverse effects in endogenous
surfactant metabolism in the mature lungs with or with-
out inflammatory injury. We also identified that iNO alle-
viated hyperoxia-associated suppression of PC synthesis
and lung injury severity through a down-regulated NF-κB
pathway for proinflammatory cytokine production. These
major findings support that, as a selective pulmonary
vasodilator, NO inhalation may be considered as a ther-
apy to regulate lung inflammation, and that, at the accu-
mulated therapeutic dose, iNO has no harm in
endogenous surfactant metabolism.
Measurement of nuclear transcription factor κB (NF-κB) in  the lung tissue at 4 (A) and 24 (B) h of different gas exposure  in control (white diagram) and lipopolysaccharides-treated  (black) rats Figure 5
Measurement of nuclear transcription factor κB (NF-κB) in 
the lung tissue at 4 (A) and 24 (B) h of different gas exposure 
in control (white diagram) and lipopolysaccharides-treated 
(black) rats. Definition of the subgroups see Fig. 1 legends. 
NF-κB DNA-binding activity was measured with electro-
phoretic mobility shift assay. The values from densitometry 
of bands are means ± SD (n = 6) and expressed as arbitrary 
units. ++ p < 0.01 versus LPS-Air; ** p < 0.01 versus LPS-O; 
## p < 0.01 versus corresponding C subgroup.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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Measurement of expression of proinflammatory cytokines of the lung tissue Figure 6
Measurement of expression of proinflammatory cytokines of the lung tissue. Definition of the subgroups see Fig. 1 legends. 
Definition of subset figures at 4 and 24 h, respectively, of different gas exposure in control (white diagram) and lipopolysaccha-
rides-treated (black) rats: A-B, tumor necrosis factor alpha (TNF-α) mRNA; C-D: cytokine-induced neutrophil chemoattract-
ant-1 (CINC-1) mRNA; E-F: interleukin-10 (IL-10) mRNA. Values are means ± SD (n = 6) and expressed as arbitrary units. + p 
< 0.05, ++ p < 0.01 versus LPS-Air; ** p < 0.01 versus LPS-O; ## p < 0.01 versus corresponding C subgroup.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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Endogenous surfactant metabolism reflects function of
AEC II. There are two major pathways of surfactant syn-
thesis and utilization in the mature lung. Reuptake and
reutilization of surfactant phospholipids by AEC II
accounts for nearly 90% of the surfactant for daily use,
and less than 10% phospholipids are synthesized through
de novo pathway [24]. In injured lungs after birth, the
pathway for reutilization of endogenous surfactant may
be disturbed, and de novo synthesis pathway may activate
again to compensate secondary surfactant deficiency and
dysfunction. In this animal model, pulmonary inflamma-
tion was obvious approximately 24 h after endotoxin
infusion and it caused further deterioration until 48 h, as
reflected by dramatic changes in surfactant synthesis
along with altered inflammatory parameters, at both 4
and 24 h of gas exposure (figures 1, 5–7), with the LPS-O
subgroup being the worst one. In septic ALI. LPS triggers
TNF-α releasing from alveolar macrophages and subse-
quently initiates an inflammatory cascade leading to dif-
fusive lung injury [23,25]. By using low-dose intratracheal
TNF-α in rats, Ulich et al showed a neutrophilic inflam-
matory infiltrate persisting up to 48 hours, accompanied
by enhanced expression of TNF-α in AEC II [26]. The
interaction among activated AM, infiltrated neutrophils,
AEC I and II and vascular endothelial cells in alveolar
space potentiate moderate to severe inflammation, ampli-
fying cascade of inflammatory reaction, and inhibiting
surfactant synthesis and causing surfactant dysfunction
[27,28].
Miles et al [29] reported that NO generator decreases
DSPC synthesis in cultured AEC II, and this result is
related to decreased level of ATP intracellularly. To date,
very few studies have focused on whether iNO may affect
de novo synthesis of PC in mature lungs in vivo with endo-
toxin-induced inflammatory injury. We found that iNO
transiently affected TPL and DSPC synthesis in LPS-
treated rats, and had no influence on the secretion of PC.
TPL and DSPC in BALF were lower in the LPS subgroups
than in the corresponding C-subgroups over time, and
these changes were more aggravated by hyperoxia, but less
influenced by iNO as it did not affect PC synthesis in the
C-subgroups. It indicates that the transient inhibition of
PC synthesis did not influence PC pool size in LPS-NO
treated rats as iNO was given at 20 ppm, the maximum
recommended therapeutic dose for neonatal lungs. It is of
interesting that iNO combined with 95% O2 inhibited PC
synthesis only transiently in this study. Exposure of 95%
O2 for 24 h (corresponding to 48 h of endotoxin adminis-
tration) resulted in a decrease of newly synthesized [3H]
PC as well as decreased PC pool size in LPS-treated rats.
However, hyperoxia for 24 h did not affect PC synthesis in
the C rats. It indicates that mature lungs with inflamma-
tory injury is prone to oxidative injury and that iNO may
alter the pathological process in this model.
Other investigations revealed that only high concentra-
tion of iNO is deleterious for mature lung, and 20 ppm of
iNO should be safe in view of using this dose as the high-
est therapeutic concentration for ALI/ARDS as in the treat-
ment of PPHN [30]. NO inhalation is usually used in
combination with high oxygen supply in critical condi-
tions, and may not be used with air. Previous experimen-
tal studies indicated that iNO at 100 ppm may improve
survival of rats in hyperoxia [31]. However, this NO dose
is irrelevant for clinical use. Issa et al [32] reported that a
brief period of hyperoxia causes an oxidant stress and
decreases the surface activity of alveolar surfactant in pre-
mature rabbits. In contrast, a low dose (14 ppm) of iNO
decreased or prevented the O2-induced detrimental effects
on alveolar surfactant and alleviated the oxidant stress.
Mechanisms explaining the protective effects of iNO
against oxidant stress my be that NO, as a weak radical
acts as a scavenger of lipid radicals, terminates the cascade
leading to lipid peroxidation. NO as a lipophilic agent is
likely to concentrate within surfactant aggregates. In con-
trast, superoxide required for the formation of peroxyni-
trite is notably hydrophilic. Inhibition of superoxide
production by neutrophils and reactions of NO inhibiting
the function of ferrous iron as a transient metal are con-
sidered as alternative mechanisms against free oxygen rad-
icals [33,34].
The biosynthesis of PC is tightly regulated within the
CDP-choline pathway. A key step in this pathway is the
conversion of choline phosphate to CDP-choline, which
is catalyzed by the rate-limiting enzyme CCT (EC
2.7.7.15). CCT localizes primarily to the endoplasmic
reticulum and nucleus, but it is also found associated with
Golgi apparatus and transport vesicles. CCT activity in
cells is controlled primarily by association with mem-
brane lipids and by gene expression. In fetal lung, the
cytosolic enzyme is in a predominantly inactive low-
molecular-mass form, whereas in adult lung the cytosolic
enzyme exists as an active high-molecular-mass multimer.
Several control mechanisms for CCT have been proposed,
including activation by reversible phosphorylation, mem-
brane translocation, calcium, enhanced gene expression,
and regulation of a variety of neutral and anionic lipids
[35]. In our experiment, the change of CCT activity is cor-
related with PC synthesis. At 4 h in LPS-NO subgroup,
iNO only decreased CCT activity in microsomes. Simi-
larly, for LPS-treated rats, hyperoxia decreased CCT activ-
ity in microsomes also, and had no effect on homogenates
and cytosolic subfraction. These results suggest that the
decrease of CCT activity may be associated with CCT
translocation from microsomes to cytosol, and forming
cytosolic L form. At 24 h after the gas exposure, LPS-sub-
groups had a uniform decrease in CCT activity in homoge-
nates, microsomal, and cytosolic subfractions in lung
tissue compared with the C-subgroups. Mechanism of LPSRespiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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induced inhibition on CCT may be different from the
interventions where either iNO or hyperoxia, or both, was
committed. Analysis with RT-PCR for CCT mRNA showed
that iNO and/or hyperoxia did not affect CCT mRNA tran-
scription. Furthermore, detection of immunoactive CCT
protein by Western blot supports the results observed
about CCT activity.
TNF-α has been implicated as a major factor for inducing
ALI. Mallampalli et al [36] found that the mechanisms by
which TNF-α inhibits CCT activity could be attributed to
regulation of protein synthesis, changes in enzyme phos-
phorylation state, or induction of lipid inhibitors for the
enzyme. Immunoblotting revealed that inhibition of CCT
activity by TNF-α was associated with a uniform decrease
in the mass of CCT in total cell lysates, cytosolic, micro-
somal fractions of murine AEC II. Northern blotting
revealed no effects of the cytokine on steady-state levels of
CCT mRNA; TNF-α did not alter de novo synthesis of
enzyme, but it substantially accelerated turnover of CCT.
We speculate that if lung inflammatory injury is allevi-
ated, the activity of CCT should be reserved.
NO can react with O2 to form cytotoxic compound, nitro-
gen dioxide (NO2), and with superoxide to form a more
potent molecule, peroxynitrite. Peroxynitrous acid and its
decomposition products are highly reactive, promoting
lipid peroxidation, nitration of tyrosine, and oxidation of
Measurement of activity of myeloperoxidase (MPO) and malondialdehyde (MDA) Figure 7
Measurement of activity of myeloperoxidase (MPO) and malondialdehyde (MDA). Definition of the subgroups see Fig. 1 leg-
ends. Definition of subset figures at 4 and 24 h, respectively, of different gas exposure in control (white diagram) and lipopoly-
saccharides-treated (black) rats: A-B, MPO; C-D, MDA. Values are means ± SD (n = 6). ++ p < 0.01 versus LPS-Air; * p < 0.05, 
** p < 0.01 versus LPS-O; ## p < 0.01 versus corresponding C subgroup.Respiratory Research 2006, 7:5 http://respiratory-research.com/content/7/1/5
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DNA. Thus, one may speculate that, when superoxide is
produced at high rate during inflammatory lung injury,
iNO might accelerate the formation of peroxynitrite and
aggravate lung damage. On the other hand, NO may act as
an antioxidant to counteract the cytotoxic effects of reac-
tive oxygen species. In vitro, NO was found to inhibit lipid
peroxidation caused by oxygen radicals and to protect
against cellular damage [37]. By serving as a free radical
scavenger, NO may decrease lipid peroxidation in vitro
[38,39]. In our investigation, significantly alleviated alve-
olar atelectasis, infiltration of neutrophils, and decreased
amount of neutropils in BALF were found in the LPS-NO
subgroup. NF-κB plays an important role in the initiation
and progression of LPS-induced ALI. Kang et al [40]
reported that iNO attenuated ALI via inhibition of NF-κB
and inflammation. Kinsella et al reported a brief exposure
to iNO (20 ppm for 4 h) decreased neutrophil accumula-
tion and decreased MPO activity in ventilated ovine lungs
with severe RDS [41]. We found that the exposure of 95%
O2 for 24 h in LPS-treated rats had increased DNA binding
activity of NF-κB and expression of mRNA of proinflam-
matory cytokines. iNO alleviated hyperoxic stress in the
lungs with inflammatory injury through inhibiting activ-
ity of NF-κB and transcriptive levels of proinflammatory
cytokine mRNAs in the lung tissue, and long term of ther-
apeutic dose of iNO may not affect de novo synthesis of
PC. Therefore we conclude that iNO should have no sub-
stantial adverse effects on metabolism and function of
endogenous surfactant phospholipids through de novo
synthesis pathway. Its anti-inflammatory effects in the
mature lungs warrant further investigation.
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